For the year ending 2025-12-31, ISCO had -$237K decrease in cash & cash equivalents over the period. -$35K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Product sales | 9,100 |
| Cost of sales | 4,033 |
| General and administrative | 3,532 |
| Selling and marketing | 1,118 |
| Research and development | 684 |
| Total operating expenses | 9,367 |
| Loss from operations | -267 |
| Other expense, net | -151 |
| Net loss | -418 |
| Stock-based compensation | 288 |
| Depreciation and amortization | 219 |
| Non-cash operating lease expense | 310 |
| Interest expense on related party note payable | 145 |
| Change in inventory reserve | 45 |
| Accounts receivable | -335 |
| Inventories | 387 |
| Prepaid expenses and other current assets | 58 |
| Accounts payable | -18 |
| Accrued liabilities | -99 |
| Operating lease liabilities | -354 |
| Net cash provided by operating activities | 8 |
| Purchases of property and equipment | 43 |
| Payments for patent licenses | 2 |
| Net cash used in investing activities | -45 |
| Principal repayment on note payable from related party | 200 |
| Net cash used in financing activities | -200 |
| Net decrease in cash | -237 |
| Cash, beginning of period | 1,230 |
| Cash, end of period | 993 |
International Stem Cell CORP (ISCO)
International Stem Cell CORP (ISCO)